[1]JournalofMedicinalChemistry,2014,vol.57,#9,p.3856-3873
[1]JournalofMedicinalChemistry,2014,vol.57,p.3856-3873
[1]Patent:US2015/38504,2015,A1.Locationinpatent:Paragraph0597-0599
[2]Patent:US2015/38505,2015,A1.Locationinpatent:Paragraph0243-0245
[3]Patent:WO2019/40298,2019,A1.Locationinpatent:Paragraph0193-0197;0199-0205
[1]Patent:US2019/55255,2019,A1.Locationinpatent:Paragraph0145;0146
[1]Jiang,Wen-Shuang;Ji,Ding-Wei;Zhang,Wei-Song;Zhang,Gong;Min,Xiang-Ting;Hu,Yan-Cheng;Jiang,Xu-Liang;Chen,Qing-An[AngewandteChemie-InternationalEdition,2021,vol.60,#15,p.8321-8328][Angew.Chem.,2021,vol.133,#15,p.8402-8409,8]
Title: Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase.
Journal: Journal of medicinal chemistry 20140508
Title: Currie KS, et al. Discovery of GS-9973, a Selective and Orally Efficacious Inhibitor of Spleen Tyrosine Kinase. J Med Chem. 2014 May 8;57(9):3856-73.
Title: Burke RT, et al. A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor. Oncotarget. 2014 Feb 28;5(4):908-15.